More potent, lipophilic and antineoplastic analog of daunorubicin. DNA-damaging effect includes DNA oxidation and methylation, DNA intercalation, inhibition of DNA synthesis, induction of DNA strand breaks and delay of cell cycle progression. Inhibitor of topoisomerase IIα. Produces endonucleolytic cleavage and is a marker of apoptosis.
Product Details
| Alternative Name: | Idamycin, DMDR, 4-Demethoxydaunorubicin |
| |
| Formula: | C26H27NO9 . HCl |
| |
| MW: | 497.5 . 36.5 |
| |
| Source: | Synthetic. |
| |
| CAS: | 57852-57-0 |
| |
| MI: | 14: 4886 |
| |
| RTECS: | HB7877000 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Determined by IR. |
| |
| Appearance: | Orange crystalline solid. |
| |
| Solubility: | Soluble in water or methanol. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Repair of idarubicin-induced DNA damage: A cause of resistance?: D.C. Dartsch & F. Gieseler; DNA Repair (Amst)
6, 1618 (2007),
Abstract;
A comparison of the in vitro genotoxicity of anticancer drugs idarubicin and mitoxantrone: J. Blasiak, et al.; Acta Biochim. Pol.
49, 145 (2002),
Abstract;
Full Text
Study of apoptosis-related responses of leukemic blast cells to in vitro anthracycline treatment: M.A. Belaud-Rotureau, et al.; Leukemia
14, 1266 (2000),
Abstract;
Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia: T. Tsuruo, et al.; Anticancer Res.
13, 357 (1993),
Abstract;
Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies: F. Ganzina, et al.; Invest. New Drugs
4, 85 (1986), Review,
Abstract;
